NCT05472506View on ClinicalTrials.gov

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2023

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Head and Neck Squamous Cell CarcinomaHead and Neck CancerHead CancerNeck CancerHead Cancer NeckNeck Carcinoma
Interventions
DRUG

IK-175 + nivolumab

IK-175 + nivolumab

Trial Locations (4)

15232

UPMC Hillman Cancer Center, Pittsburgh

60637

University of Chicago Medical Center, Chicago

63130

Washington University, St Louis

98109

Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

Ikena Oncology

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Ikena Oncology

INDUSTRY

NCT05472506 - Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | Biotech Hunter | Biotech Hunter